4D Molecular Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of 4D-110 by Intravitreal Injection for the Treatment of Choroideremia
EMERYVILLE, Calif.–(BUSINESS WIRE)–4D Molecular Therapeutics (4DMT), a clinical-stage leader in the development of precision-guided AAV…
Advancing Brain–Computer Interfaces for Rehabilitation and Assistive Technologies
HeyNews Launches AdApt to Rewrite Sponsor Ad Copy in Newsletter Publishers’ Own Voice